Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,093 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
Kobayashi K, Miyagawa N, Mitsui K, Matsuoka M, Kojima Y, Takahashi H, Ootsubo K, Nagai J, Ueno H, Ishibashi T, Sultana S, Okada Y, Akimoto S, Okita H, Matsumoto K, Goto H, Kiyokawa N, Ohara A. Kobayashi K, et al. Among authors: okada y. Pediatr Blood Cancer. 2015 Jun;62(6):1058-60. doi: 10.1002/pbc.25327. Epub 2014 Nov 14. Pediatr Blood Cancer. 2015. PMID: 25400122
Expression of bioactive soluble human stem cell factor (SCF) from recombinant Escherichia coli by coproduction of thioredoxin and efficient purification using arginine in affinity chromatography.
Akuta T, Kikuchi-Ueda T, Imaizumi K, Oshikane H, Nakaki T, Okada Y, Sultana S, Kobayashi K, Kiyokawa N, Ono Y. Akuta T, et al. Among authors: okada y. Protein Expr Purif. 2015 Jan;105:1-7. doi: 10.1016/j.pep.2014.09.015. Epub 2014 Oct 5. Protein Expr Purif. 2015. PMID: 25286400
Monocyte Chemoattractant Protein-1 (MCP-1) as a Potential Therapeutic Target and a Noninvasive Biomarker of Liver Fibrosis Associated With Transient Myeloproliferative Disorder in Down Syndrome.
Kobayashi K, Yoshioka T, Miyauchi J, Nakazawa A, Yamazaki S, Ono H, Tatsuno M, Iijima K, Takahashi C, Okada Y, Teranishi K, Matsunaga T, Matsushima C, Inagaki M, Suehiro M, Suehiro S, Nishitani M, Kubota H, Iio J, Nishida Y, Katayama T, Takada N, Watanabe K, Yamamoto T, Yasumizu R, Matsuoka K, Ohki K, Kiyokawa N, Maihara T, Usami I. Kobayashi K, et al. Among authors: okada y. J Pediatr Hematol Oncol. 2017 Jul;39(5):e285-e289. doi: 10.1097/MPH.0000000000000809. J Pediatr Hematol Oncol. 2017. PMID: 28267084
3-Fr steerable microcatheter system via the upper limb artery in RADPLAT for right maxillary cancer.
Takahashi M, Nakazawa K, Usami Y, Natsuyama Y, Tsukamoto Y, Suzuki J, Asami S, Inoue H, Matsumura S, Nakahira M, Saito T, Kato S, Okada Y, Tajima H, Kozawa E, Baba Y. Takahashi M, et al. Among authors: okada y. Minim Invasive Ther Allied Technol. 2024 May 28:1-8. doi: 10.1080/13645706.2024.2359718. Online ahead of print. Minim Invasive Ther Allied Technol. 2024. PMID: 38804569
Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors.
Takeshima R, Kamata M, Suzuki S, Ito M, Watanabe A, Uchida H, Chijiwa C, Okada Y, Azuma S, Nagata M, Egawa S, Hiura A, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Ishikawa T, Tada Y. Takeshima R, et al. Among authors: okada y. J Dermatol. 2024 May 28. doi: 10.1111/1346-8138.17277. Online ahead of print. J Dermatol. 2024. PMID: 38804254
Prognostic significance of chronic kidney disease and impaired renal function in Japanese patients with COVID-19.
Tanaka H, Chubachi S, Asakura T, Namkoong H, Azekawa S, Otake S, Nakagawara K, Fukushima T, Lee H, Watase M, Sakurai K, Kusumoto T, Masaki K, Kamata H, Ishii M, Hasegawa N, Okada Y, Koike R, Kitagawa Y, Kimura A, Imoto S, Miyano S, Ogawa S, Kanai T, Fukunaga K. Tanaka H, et al. Among authors: okada y. BMC Infect Dis. 2024 May 25;24(1):527. doi: 10.1186/s12879-024-09414-w. BMC Infect Dis. 2024. PMID: 38796423 Free PMC article.
Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trial.
Tanaka A, Shimabukuro M, Teragawa H, Yoshida H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, Node K; EMBLEM Investigators. Tanaka A, et al. Among authors: okada y. Hypertens Res. 2024 May 24. doi: 10.1038/s41440-024-01725-4. Online ahead of print. Hypertens Res. 2024. PMID: 38789538
7,093 results